RxDoctor Payments Data

Joyia Montanez

Nurse Practitioner · Pinehurst, NCNPI 1225699853

Payments from drug & device makers

$4,132in general payments, 2019–2025

Across 229 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$765
  • Pfizer$352
  • Novartis$300
  • Biogen$254
  • MDD US Operations, LLC$250
  • Insightec,inc$181
  • plus $2K from 39 others

What the payments were for

  • Speaking & faculty fees$271%
  • Food & beverage$4,01897%
  • Education$872%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,132 in reported general payments places this provider in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$49,307
Medicare patients
127
Services billed
4,408

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5014$132,474
Nurtec OdtRimegepant Sulfate58$102,776
AptiomEslicarbazepine Acetate42$99,794
UbrelvyUbrogepant61$78,668
Ajovy AutoinjectorFremanezumab-Vfrm54$64,604
Aimovig AutoinjectorErenumab-Aooe51$38,909
QuliptaAtogepant35$37,013
Topiramate ErTopiramate32$28,317
Emgality PenGalcanezumab-Gnlm37$28,238
BriviactBrivaracetam14$22,491
NeuproRotigotine16$20,151
Glatiramer Acetate11$15,310
BotoxOnabotulinumtoxina11$14,416
Levetiracetam559$12,693
Oxtellar XrOxcarbazepine11$12,309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox, Namzaric$765$136,311118 claims
PfizerNurtec Odt, Dilantin$352$106,72572 claims
UCB, Inc.Briviact, Neupro$69$42,64230 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$46$12,30911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Pinehurst

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →